Essex Bio-Tech Buys Back 350,000 Shares, Treasury Stock Expands to 1.36 Million

Bulletin Express07-02

Essex Bio-Technology Limited reported a share repurchase of 350,000 ordinary shares on 2 July 2026 through on-market transactions on the Hong Kong Stock Exchange, according to its latest Next Day Disclosure Return.

The repurchase was executed at prices ranging from HK$2.50 to HK$2.61 per share, translating into a volume-weighted average cost of HK$2.5586 per share and a total cash outlay of HK$0.90 million.

Key capital changes after the transaction: • Issued shares (excluding treasury shares) fell from 566.00 million to 565.65 million, a marginal decline of 0.06%. • Treasury shares increased from 1.01 million to 1.36 million. • Total issued shares remained unchanged at 567.01 million.

The repurchase forms part of the mandate approved on 26 May 2026, which authorises Essex Bio-Tech to buy back up to 56.70 million shares. Including the latest transaction, the company has repurchased 1.36 million shares under this mandate, representing approximately 0.24% of the shares outstanding on the mandate date.

All 350,000 shares acquired on 2 July 2026 were retained as treasury shares; no cancellations have occurred. In line with Hong Kong listing rules, Essex Bio-Tech is subject to a moratorium on new share issues or treasury share sales until 1 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157463573?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157463573","market":"us","top_or_hot":-1,"title":"Essex Bio-Tech Buys Back 350,000 Shares, Treasury Stock Expands to 1.36 Million","media":"Bulletin Express","content":"<p>Essex Bio-Technology Limited reported a share repurchase of 350,000 ordinary shares on 2 July 2026 through on-market transactions on the Hong Kong Stock Exchange, according to its latest Next Day Disclosure Return.</p>\n<p>The repurchase was executed at prices ranging from HK$2.50 to HK$2.61 per share, translating into a volume-weighted average cost of HK$2.5586 per share and a total cash outlay of HK$0.90 million.</p>\n<p>Key capital changes after the transaction:\n• Issued shares (excluding treasury shares) fell from 566.00 million to 565.65 million, a marginal decline of 0.06%.  \n• Treasury shares increased from 1.01 million to 1.36 million.  \n• Total issued shares remained unchanged at 567.01 million.</p>\n<p>The repurchase forms part of the mandate approved on 26 May 2026, which authorises Essex Bio-Tech to buy back up to 56.70 million shares. Including the latest transaction, the company has repurchased 1.36 million shares under this mandate, representing approximately 0.24% of the shares outstanding on the mandate date.</p>\n<p>All 350,000 shares acquired on 2 July 2026 were retained as treasury shares; no cancellations have occurred. In line with Hong Kong listing rules, Essex Bio-Tech is subject to a moratorium on new share issues or treasury share sales until 1 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Essex Bio-Tech Buys Back 350,000 Shares, Treasury Stock Expands to 1.36 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEssex Bio-Tech Buys Back 350,000 Shares, Treasury Stock Expands to 1.36 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-02 17:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Essex Bio-Technology Limited reported a share repurchase of 350,000 ordinary shares on 2 July 2026 through on-market transactions on the Hong Kong Stock Exchange, according to its latest Next Day Disclosure Return.</p>\n<p>The repurchase was executed at prices ranging from HK$2.50 to HK$2.61 per share, translating into a volume-weighted average cost of HK$2.5586 per share and a total cash outlay of HK$0.90 million.</p>\n<p>Key capital changes after the transaction:\n• Issued shares (excluding treasury shares) fell from 566.00 million to 565.65 million, a marginal decline of 0.06%.  \n• Treasury shares increased from 1.01 million to 1.36 million.  \n• Total issued shares remained unchanged at 567.01 million.</p>\n<p>The repurchase forms part of the mandate approved on 26 May 2026, which authorises Essex Bio-Tech to buy back up to 56.70 million shares. Including the latest transaction, the company has repurchased 1.36 million shares under this mandate, representing approximately 0.24% of the shares outstanding on the mandate date.</p>\n<p>All 350,000 shares acquired on 2 July 2026 were retained as treasury shares; no cancellations have occurred. In line with Hong Kong listing rules, Essex Bio-Tech is subject to a moratorium on new share issues or treasury share sales until 1 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01061","symbol_name":"亿胜生物科技","start_time":0,"source_url":"","article_id":"1157463573","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157463573","pubTimestamp":1782985537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Essex Bio-Technology Limited reported a share repurchase of 350,000 ordinary shares on 2 July 2026 through on-market transactions on the Hong Kong Stock Exchange, according to its latest Next Day...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01061":"亿胜生物科技"},"translate_title":"Essex Bio-Tech回购35万股，库存股扩大至136万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01061":1},"content_text":"Essex Bio-Technology Limited reported a share repurchase of 350,000 ordinary shares on 2 July 2026 through on-market transactions on the Hong Kong Stock Exchange, according to its latest Next Day Disclosure Return.\nThe repurchase was executed at prices ranging from HK$2.50 to HK$2.61 per share, translating into a volume-weighted average cost of HK$2.5586 per share and a total cash outlay of HK$0.90 million.\nKey capital changes after the transaction:\n• Issued shares (excluding treasury shares) fell from 566.00 million to 565.65 million, a marginal decline of 0.06%.  \n• Treasury shares increased from 1.01 million to 1.36 million.  \n• Total issued shares remained unchanged at 567.01 million.\nThe repurchase forms part of the mandate approved on 26 May 2026, which authorises Essex Bio-Tech to buy back up to 56.70 million shares. Including the latest transaction, the company has repurchased 1.36 million shares under this mandate, representing approximately 0.24% of the shares outstanding on the mandate date.\nAll 350,000 shares acquired on 2 July 2026 were retained as treasury shares; no cancellations have occurred. In line with Hong Kong listing rules, Essex Bio-Tech is subject to a moratorium on new share issues or treasury share sales until 1 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157463573","isCrawlerRequest":true}